Daptomycin in bone and joint infections: A review of the literature

Archives of Orthopaedic and Trauma Surgery

Volumn 129, Issue 11, 2009, Pages 1495-1504

  Rice, Dennis A K ^a,b   Mendez Vigo, Luke ^c  

^a St Joseph's/Candler Health System   (United States)

^b Ortho McNeil Janssen LLC   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Bone; Daptomycin; Infection; MRSA; Osteomyelitis; VRE

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BONE CEMENT; CILASTATIN PLUS IMIPENEM; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; PENICILLIN G; POLY(METHYL METHACRYLATE); RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANEMIA; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTHRALGIA; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; BONE AND JOINT INFECTIONS; BONE INFECTION; BONE MARROW SUPPRESSION; CATHETER INFECTION; CHRONIC OSTEOMYELITIS; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; FEVER; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; SKIN INFECTION; STAPHYLOCOCCAL BACTEREMIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BONE CEMENTS; BONE DISEASES; DAPTOMYCIN; DRUG CARRIERS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; JOINT DISEASES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; POLYMETHYL METHACRYLATE; STAPHYLOCOCCAL INFECTIONS;

EID: 70349935159     PISSN: 09368051     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00402-008-0772-x     Document Type: Review

References (94)

1. Davis JS (2005) Management of bone and joint infections due to Staphylococcus aureus. Intern Med J 35(suppl 2):S79-S96. doi: 10.1111/ j.1444-0903.2005.00982.x
2. Razonable RR, Osmon DR, Steckelberg JM (2004) Linezolid therapy for orthopedic infections. Mayo Clin Proc 79:1137-1144
3. Sievert DM, Boulton ML, Stoltman G et al (2002) Staphylococcus aureus resistant to vancomycin - United States 2002. Morb Mortal Wkly Rep 51:565-567
4. Rice LB (2006) Antimicrobial resistance in Gram-positive bacteria. Am J Infect Control 34(suppl 5):S11-S19. doi: 10.1016/j.ajic.2006.05.220
5. Tenover FC, McDougal LK, Goering RV et al (2006) Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 44:108-118. doi: 10.1128/JCM.44.1.108-118.2006
6. Styers D, Sheehan DJ, Hogan P, Sahm DF (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 5:2. doi: 10.1186/1476-0711-5-2
7. Moran GJ, Krishnadasan A, Gorwitz RJ, EMERGEncy ID Net Study Group et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674. doi: 10.1056/NEJMoa055356
8. Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665. doi: 10.1056/ NEJMoa053783
9. Smith TL, Pearson ML, Wilcox KR et al (1999) Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340:493-501. doi: 10.1056/NEJM199902183400701
10. Nishimura S, Tsurumoto T, Yonekura A, Adachi K, Shindo H (2006) Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J Orthop Sci 11:46-50. doi: 10.1007/s00776-005-0968-7
11. Marra A, Dib-Hajj F, Lamb L et al (2007) Enterococcal virulence determinants may be involved in resistance to clinical therapy. Diagn Microbiol Infect Dis 58:59-65. doi: 10.1016/j.diagmicrobio.2006.11.024
12. Weigel LM, Donlan RM, Shin DH et al (2007) High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 51:231-238. doi: 10.1128/AAC.00576-06
13. Tomasz A, Albino A, Zanati E (1970) Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 227:138-140. doi: 10.1038/227138a0
14. Tuomanen E, Durack DT, Tomasz A (1986) Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 30:521-527
15. Goldenberg DL (1998) Septic arthritis. Lancet 351:197-202. doi: 10.1016/ S0140-6736(97)09522-6
16. Mader JT, Shirtliff ME, Bergquist S, Calhoun JH (2000) Bone and joint infections in the elderly: Practical treatment guidelines. Drugs Aging 16:67-80. doi: 10.2165/00002512-200016010-00006
17. Youssef PP, York JR (1994) Septic arthritis: A second decade of experience. Aust N Z J Med 24:307-311
18. Gottlieb T, Atkins BL, Shaw DR (2002) Soft tissue, bone and joint infections. Med J Aust 176:609-615
19. Hamed KA, Tam JY, Prober CG (1996) Pharmacokinetic optimisation of the treatment of septic arthritis. Clin Pharmacokinet 21:156-163. doi: 10.2165/00003088-199631020-00006
20. Lazzarini L, Lipsky BA, Mader JT (2005) Antibiotic treatment of osteomyelitis: What have we learned from 30 years of clinical trials. Int J Infect Dis 9:127-138. doi: 10.1016/j.ijid.2004.09.009
21. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F (2001) Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 1:175-188. doi: 10.1016/ S1473-3099(01)00094-9
22. Appelbaum PC (2006) MRSA - the tip of the iceberg. Clin Microbiol Infect 12(suppl 2):3-10. doi: 10.1111/j.1469-0691.2006.01402.x
23. Hiramatsu K (2001) Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis 1:147-155. doi: 10.1016/S1473-3099(01)00091-3
24. Weigel LM, Clewell DB, Gill SR et al (2003) Genetic analysis of a high level vancomycin-resistant isolate of Staphylococcus aureus. Science 28:1569-1571. doi: 10.1126/science.1090956
25. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-136. doi: 10.1093/jac/40.1.135
26. Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML (2001) Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 175:480-483
27. Darley E, MacGowan A (2004) Antibiotic treatment of Gram-positive bone and joint infection. J Antimicrob Chemother 53:928-935. doi: 10.1093/jac/ dkh191
28. Henry N, Roues M, Whitesell A (1987) Treatment of methicillin resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampicin. Am J Med 82(suppl 4A):73-75
29. Package insert (2003) Vancocin (vancomycin). Eli Lilly and Co, Indianapolis
30. Cunha BA (2005) Methicillin-resistant Staphylococcus aureus: Clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11(suppl 4):33-42. doi: 10.1111/j.1469-0691.2005.01162.x
31. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF (2007) Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 13:491-493
32. Sakoulas G, Moise-Broder PA, Schentag J et al (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398-2402. doi: 10.1128/JCM.42.6.2398-2402.2004
33. Finney MS, Crank CW, Segreti J (2005) Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 21:1923-1926. doi: 10.1185/030079905X74961
34. Package insert (2003) Synercid (quinupristin/dalfopristin) Monarch Pharmaceuticals, Bristol
35. Bouanchaud DH (1997) In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother 39(suppl A):15-21. doi: 10.1093/jac/39.suppl_1.15
36. Saleh-Mghir A, Ameur N, Muller-Serieys C et al (2002) Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 46:1122-1124. doi: 10.1128/ AAC.46.4.1122-1124.2002
37. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH (2000) Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 46:775-784. doi: 10.1093/jac/46.5.775
38. Bassetti M, Righi E, DiBiagio A, Rosso R, Beltrame A, Bassetti D (2005) Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect Ther 3:343-352. doi: 10.1586/14787210.3.3.343
39. Package insert (2007) Zyvox (linezolid). Pharmacia & Upjohn Co Div of Pfizer Inc., New York
40. Senneville E, Legout L, Valette M et al (2006) Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 28:1155-1163. doi: 10.1016/ j.clinthera.2006.08.001
41. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ (2007) Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 29:233-239. doi: 10.1016/j.ijantimicag.2006.08.030
42. Prystowsky J, Siddiqui F, Chosay J et al (2001) Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45:2154-2156. doi: 10.1128/AAC.45.7.2154-2156.2001
43. Tsiodras S, Gold HS, Sakoulas G et al (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208. doi: 10.1016/S0140-6736(01)05410-1
44. Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH (2005) Comparative evaluation of tigecycline and vancomycin with and without rifampicin, in the treatment of methicillin resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55:995-1002. doi: 10.1093/jac/dki109
45. Package insert (2007) Tygacil (tigecycline). Wyeth Pharmaceuticals, Philadelphia
46. Doan TL, Fung HB, Mehta D, Riska PF (2006) Tigecycline: A glycylcycline antimicrobial agent. Clin Ther 28:1079-1106. doi: 10.1016/ j.clinthera.2006.08.011
47. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR (1992) Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36:318-325
48. Tedesco KL, Rybak MJ (2004) Daptomycin. Pharmacotherapy 24:41-57. doi: 10.1592/phco.24.1.41.34802
49. Silverman JA, Oliver N, Andrew T, Li T (2001) Resistance studies with daptomycin. Antimicrob Agents Chemother 45:1799-1802. doi: 10.1128/ AAC.45.6.1799-1802.2001
50. Ammerlaan HS, Bonten MJ (2006) Daptomycin: Graduation day. Clin Microbiol Infect 12(suppl 8):22-28. doi: 10.1111/j.1469-0691.2006.01627.x
51. Rybak MJ, Hershberger E, Moldovan T et al (2000) In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44:1062-1066. doi: 10.1128/AAC.44.4.1062-1066.2000
52. Pfaller MA, Sader HS, Jones RN (2007) Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 57:459-465. doi: 10.1016/j.diagmicrobio.2006.10.007
53. Credito K, Lin G, Appelbaum PC (2007) Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 51:1504-1507. doi: 10.1128/AAC.01455-06
54. Rand KH, Houck HJ (2004) Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48:2871-2875. doi: 10.1128/ AAC.48.8.2871-2875.2004
55. Tally FP, DeBruin MF (2000) Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 46:523-526. doi: 10.1093/jac/46.4.523
56. Tally FP, Zeckel M, Wasilewski MM et al (1999) Daptomycin: A novel agent for Gram-positive infections. Expert Opin Investig Drugs 8:1223-1238. doi: 10.1517/13543784.8.8.1223
57. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948-2953. doi: 10.1128/AAC.44.11.2948-2953.2000
58. Alder J, Li T, Yu D et al (2003) Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother 47:3561-3656. doi: 10.1128/AAC.47.11.3561-3566.2003
59. Cha R, Grucz RG Jr, Rybak MJ (2003) Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 47:1598-1603. doi: 10.1128/AAC.47.5.1598-1603.2003
60. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP (2003) Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52:405-411. doi: 10.1093/jac/dkg337
61. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ (1990) Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 34:2081-2085
62. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL (2001) Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45:845-851. doi: 10.1128/ AAC.45.3.845-851.2001
63. Mader JT, Adams K (1989) Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 33:689-692
64. Smith K, Cobbs G, Dill R, Lyon D, Graves A, Avent K (1990) Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy 36:428-434
65. Luu QN, Buxton TB, Nelson DR, Rissing JP (1989) Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 8:562-563. doi: 10.1007/ BF01967482
66. Safdar N, Andes D, Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48:63-68. doi: 10.1128/ AAC.48.1.63-68.2004
67. Schaad HJ, Bento M, Lew DP, Vaudaux P (2006) Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis 116:74. doi: 10.1186/1471-2334-6-74
68. Yin L-Y, Calhoun JH, Tongchuan LI et al (2001) Comparative efficacies of vancomycin and cubicin, a novel lipopeptide antibiotic, in the treatment of methicillin-resistant Staphylococcus aureus: Studies with a rabbit model. Presented at 39th annual meeting of the Infectious Diseases Society of America, San Francisco, 25-28 October, Abstract 358
69. Boucher HW, Abrutyn E, Savor-Price C et al (2006) Outcomes with daptomycin vs. standard therapy for S. aureus bone and joint infections. Presented at 44th Annual Meeting of the Infectious Diseases Society of America Meeting, Toronto, Ontario, October 12-15. Abstract 377
70. Balter L, Donovan B, North D et al (2006) Retrospective evaluation of daptomycin efficacy and safety in patients with osteomyelitis. Presented at 44th annual meeting of the Infectious Diseases Society of America Meeting, Toronto, ON, Canada, 12-15 October, Abstract 208
71. Antony SJ, Angelos E, Stratton CW (2006) Clinical experience with daptomycin in patients with orthopedic related infections. Infect Dis Clin Pract 14:144-149. doi: 10.1097/01.idc.0000206490.05422.df
72. Rao N, Regalla DM (2006) Uncertain efficacy of daptomycin for prosthetic joint infections: A prospective case series. Clin Orthop Relat Res 451:34-37. doi: 10.1097/01.blo.0000224021.73163.61
73. Holtom PD, Zalavras CG, Lamp KC, Park N, Friedrich LV (2007) Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: A preliminary study. Clin Orthop Relat Res 461:35-39
74. Burns C (2008) Long-term use of daptomycin for MRSA osteomyletis and joint infection. Scand J Infect Dis 40:183-186. doi: 10.1080/ 00365540701633038
75. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R (2007) Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 120(10A):S13-S20. doi: 10.1016/j.amjmed.2007.07.010
76. Joseph TN, Chen AL, Di Cesare PE (2003) Use of antibiotic-impregnated cement in total joint arthroplasty. J Am Acad Orthop Surg 11:38-47
77. Hall EW, Rouse MS, Jacofsky DJ et al (2004) Release of daptomycin from polymethyl-methacralate beads in a continuous flow chamber. Diagn Microbiol Infect Dis 50:261-265. doi: 10.1016/j.diagmicrobio.2004.03.004
78. Perry AC, Rouse MS, Khaliq Y et al (2002) Antimicrobial release kinetics from polymethylmethacrylate in a novel continuous flow chamber. Clin Orthop Relat Res 403:49-53. doi: 10.1097/00003086-200210000-00009
79. Webb ND, McCanless JD, Courtney HS, Bumgardner JD, Haggard WO (2008) Daptomycin eluted from calcium sulfate appears effective against staphylococcus. Clin Orthop Relat Res 466:1383-1387. doi: 10.1007/ s11999-008-0245-0
80. Vikram HR, Havill NL, Koeth LM, Boyce JM (2005) Clinical progression of methicillin resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43:5384-5387. doi: 10.1128/JCM.43.10.5384-5387.2005
81. Marty FM, Yeh WW, Wennerstein CB et al (2006) Emergence of a clinical daptomycin resistant Staphylococcus aureus isolate during treatment of methicillin resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44:595-597. doi: 10.1128/ JCM.44.2.595-597.2006
82. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA (2005) Development of daptomycin resistance in vivo in methicillin resistant Staphylococcus aureus. J Clin Microbiol 43:5285-5287. doi: 10.1128/ JCM.43.10.5285-5287.2005
83. Cui L, Tominaga E, Neoh HM, Hiramatsu K (2006) Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50:1079-1082. doi: 10.1128/AAC.50.3.1079-1082.2006
84. Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208-1215. doi: 10.1086/513203
85. Wootton M, MacGowan AP, Walsh TR (2006) Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) isolates. Antimicrob Agents Chemother 50:4195-4197. doi: 10.1128/AAC.00678-06
86. Sader HS, Jones RN (2006) The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis 43:798-799. doi: 10.1086/507109
87. Sader HS, Fritsche TR, Jones RN (2005) Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn Microbiol Infect Dis 53:329-332. doi: 10.1016/j.diagmicrobio.2005.07.001
88. Sakoulas G, Brown J, Lamp KC et al (2006) Efficacy and safety of daptomycin in patients treated for non-catheter-related bacteremia. In: Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, 27-30 September, Abstract 1536
89. Mohan SS, McDermott BP, Cunha BA (2005) Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 34:69-71. doi: 10.1016/j.hrtlng.2004.07.009
90. Boucher HW, Sakoulas G (2007) Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45:601-608. doi: 10.1086/520655
91. Rehm SJ, Boucher H, Levine DP et al (2006) Daptomycin vs. vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. In: Program and abstracts of the 44th annual meeting of the Infectious Diseases Society of America, Toronto, ON, Canada, 12-15 October, Abstract 139
92. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM (2006) Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581-1585. doi: 10.1128/AAC.50.4.1581-1585.2006
93. Sader HS, Watters AA, Fritsche TR, Jones RN (2007) Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci, vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 7:29. doi: 10.1186/1471-2334-7-29
94. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA (2003) Baseline study to determine in vitro activities of daptomycin against Gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 47:1689-1693. doi: 10.1128/ AAC.47.5.1689-1693.2003